Form 8-K - Current report:
SEC Accession No. 0000950170-22-020699
Filing Date
2022-11-01
Accepted
2022-11-01 07:14:10
Documents
13
Period of Report
2022-11-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pyxs-20221101.htm   iXBRL 8-K 58290
2 EX-99.1 pyxs-ex99_1.htm EX-99.1 261605
  Complete submission text file 0000950170-22-020699.txt   453388

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pyxs-20221101_lab.xml EX-101.LAB 14018
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pyxs-20221101_pre.xml EX-101.PRE 10289
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pyxs-20221101.xsd EX-101.SCH 2472
7 EXTRACTED XBRL INSTANCE DOCUMENT pyxs-20221101_htm.xml XML 4917
Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

EIN.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40881 | Film No.: 221348480
SIC: 2834 Pharmaceutical Preparations